ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > ENDPOINTS NEWS Jan 31, 2024

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Feb 08, 2024 2:15pm

93 Views

Post# 35870566

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ENDPOINTS NEWS Jan 31, 2024

You're off by a year. It joined the Nasdaq in 2022, not 2023. Check your prices again.

https://www.promisneurosciences.com/news-media/press-releases/detail/185/promis-neurosciences-to-commence-trading-on-nasdaq-under

"The Company’s Common Shares will begin trading on Friday, July 8th, 2022, under the symbol “PMN”."

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?